Kathryn E. Foulds

Kathryn E. Foulds

Auto-generated profile, based on publicly available information

Kathryn E. Foulds

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in Science
Verified
Journal Article
Open access
PDF file
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
MNMartha C. Nason
Martha C. Nason
BFBritta Flach
Britta Flach
MGMatthew Gagne
Matthew Gagne
SOSarah O’connell
Sarah O’connell
RSRobert Seder
Robert Seder
Antibodies dovetail with protection: Immune correlates of protection are clinical end points used to gauge vaccine-induced immunogenicity and protection. Corbett et al . studied nonhuman primate (NHP) immune responses to various doses of the mRNA-1273 (Moderna) vaccine to provide a range of immune responses and protective outcomes. They determined that circulating spike protein–specific antibodies correlated with protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in the airways. Passively transferred NHP antibodies were sufficient to mediate protection against SARS-CoV-2 challenge in hamsters, emphasizing that antibodies are mechanistic correlates. Protection of the lower respiratory tract required lower serum antibody concentrations, possibly explaining why most current vaccines are highly effective against severe lower airway disease. The higher antibody threshold required for reducing upper airway infection has potential implications for boosting to limit transmission. —STS

10 December 2021 in Science
Verified
Journal Article
Closed access
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
MGMatthew Gagne
Matthew Gagne
DWDanielle A. Wagner
Danielle A. Wagner
SCSarah O’ Connell
Sarah O’ Connell
SNSandeep R. Narpala
Sandeep R. Narpala
RSRobert Seder
Robert Seder
A look at variant-specific boosters: The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) has raised the question of whether current COVID-19 vaccines protect against VOCs and if a variant specific vaccine may be needed. Of the currently identified VOCs, the Delta variant is believed to be the most transmissible, whereas the Beta variant appears to be the most vaccine resistant. Corbett et al . looked at the effect of vaccine boosting using either the original WA-1 strain vaccine or a Beta variant–specific booster. Around 6 months after the primary two-dose vaccine series, a third boost vaccination resulted in higher neutralizing antibody levels against VOCs in nonhuman primates. Regardless of whether the boost was from the original vaccine or the Beta-specific version, similar increases in neutralizing antibody levels were observed and resulted in enhanced viral protection. —PNK

20 August 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
AWAnne P. Werner
Anne P. Werner
SCSarah O’ Connell
Sarah O’ Connell
MGMatthew Gagne
Matthew Gagne
LLLilin Lai
Lilin Lai
RSRobert Seder
Robert Seder

27 July 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
JFJoseph Francica
Joseph Francica
BFBarbara J. Flynn
Barbara J. Flynn
KFKathryn E. Foulds
Kathryn E. Foulds
ANAmy T. Noe
Amy T. Noe
AWAnne P. Werner
Anne P. Werner
RSRobert Seder
Robert Seder
Adjuvanted soluble protein vaccines have been used extensively in humans for protection against various viral infections based on their robust induction of antibody responses. Here, soluble prefusion-stabilized spike protein trimers (preS dTM) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were formulated with the adjuvant AS03 and administered twice to nonhuman primates (NHP). Binding and functional neutralization assays and systems serology revealed that the vaccinated NHP developed AS03-dependent multi-functional humoral responses that targeted distinct domains of the spike protein and bound to a variety of FC receptors mediating immune cell effector functions in vitro. The neutralizing 50% inhibitory concentration (IC50) titers for pseudovirus and live SARS-CoV-2 were higher than titers for a panel of human convalescent serum samples. NHP were challenged intranasally and intratracheally with a high dose (3x106 plaque forming units, PFU) of SARS-CoV-2 (USA-WA1/2020 isolate). Two days post-challenge, vaccinated NHP showed rapid control of viral replication in both the upper and lower airways. Notably, vaccinated NHP also had increased spike protein-specific IgG antibody responses in the lung as early as two days post challenge. Moreover, passive transfer of vaccine-induced IgG to hamsters mediated protection from subsequent SARS-CoV-2 challenge. These data show that antibodies induced by the AS03-adjuvanted preS dTM vaccine were sufficient to mediate protection against SARS-CoV-2 in NHP and that rapid anamnestic antibody responses in the lung may be a key mechanism for protection.

18 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KRKoen K.A. Van Rompay
Koen K.A. Van Rompay
RKRebekah I. Keesler
Rebekah I. Keesler
Amir ArdeshirAmir Ardeshir
Amir Ardeshir
JWJennifer Watanabe
Jennifer Watanabe
JUJodie Usachenko
Jodie Usachenko
BGBarney S. Graham
Barney S. Graham
A Zika virus vaccine administered to macaques before conception reduces maternal viremia and improves fetal outcomes.

10 June 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SMSonia Maciejewski
Sonia Maciejewski
TRTracy Ruckwardt
Tracy Ruckwardt
KMKaitlyn Morabito
Kaitlyn Morabito
BFBryant M. Foreman
Bryant M. Foreman
KBKatherine E. Burgomaster
Katherine E. Burgomaster
TPTheodore C. Pierson
Theodore C. Pierson
Analysis of antibodies elicited by related Zika virus DNA vaccines revealed protection correlates with a capacity to neutralize mature virions.